Intensity Therapeutics, Inc. (INTS) Income Statement
INTS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsINTS revenue and net income
INTS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
INTS quarterly EPS vs estimates
Intensity Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.94).
INTS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $26,000 | $25,000 | $147,000 | $179,037 | — | — | — |
| Gross profit | −$26,000 | −$25,000 | −$147,000 | −$179,037 | — | — | — |
| Research & development | $6.8M | $10.5M | $4.8M | $5.1M | $5.9M | $5.1M | $4.4M |
| Sales, general & admin | $5.2M | $6.1M | $3.5M | $2.4M | $2.2M | $1.2M | $1.2M |
| Total operating expenses | $12.0M | $16.6M | $8.2M | $7.5M | $8.0M | $6.2M | $5.7M |
| Operating income | −$12.0M | −$16.6M | −$8.3M | −$7.5M | −$8.0M | −$6.2M | −$5.7M |
| Interest income | $180,000 | $314,000 | $324,000 | $2,481 | $2,609 | $74,009 | $150,707 |
| Interest expense | — | $0 | $305,000 | $81,781 | $16,767 | — | — |
| Income before taxes | −$11.6M | −$16.3M | −$10.5M | −$7.6M | −$7.9M | −$6.0M | −$5.4M |
| Income taxes | — | — | $1 | −$131,908 | −$2,609 | −$74,009 | −$150,707 |
| Net income | −$11.6M | −$16.3M | −$10.5M | −$7.6M | −$7.9M | −$6.0M | −$5.2M |
| EBITDA | −$11.6M | −$16.3M | −$10.1M | −$7.3M | −$8.0M | −$6.2M | −$5.7M |
| EPS (diluted) | −$8.34 | −$24.92 | −$31.85 | −$55.59 | −$57.87 | −$43.67 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $24,000 | $0 | $0 | $0 | $282,216 | $0 |
| Cost of revenue | $7,000 | $7,000 | $7,000 | $6,000 | $7,000 | $6,000 | $12,000 | $7,000 | $6,000 | $6,000 | $5,892 | $2,019 |
| Gross profit | −$7,000 | −$7,000 | −$7,000 | −$6,000 | −$7,000 | −$6,000 | $12,000 | −$7,000 | −$6,000 | −$6,000 | $276,324 | −$2,019 |
| Research & development | $1.8M | $1.2M | $1.5M | $1.6M | $1.5M | $2.2M | $2.0M | $2.2M | $3.6M | $2.8M | $1.8M | $1.4M |
| Sales, general & admin | $1.3M | $1.3M | $1.6M | $1.2M | $1.2M | $1.2M | $1.2M | $1.4M | $1.5M | $1.9M | $1.6M | $1.1M |
| Total operating expenses | $3.1M | $2.5M | $3.1M | $2.7M | $2.7M | $3.4M | $3.2M | $3.6M | $5.1M | $4.7M | $3.4M | $2.5M |
| Operating income | −$3.1M | −$2.5M | −$3.1M | −$2.7M | −$2.7M | −$3.4M | −$3.2M | −$3.6M | −$5.1M | −$4.7M | −$3.4M | −$2.5M |
| Interest income | $77,000 | $94,000 | $88,000 | $59,000 | $17,000 | $15,000 | $28,000 | $48,000 | $98,000 | $140,000 | $175,974 | $147,539 |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $161 | $0 |
| Income before taxes | −$3.0M | −$2.4M | −$3.1M | −$2.7M | −$2.5M | −$3.3M | −$3.2M | −$3.5M | −$5.0M | −$4.6M | −$3.2M | −$2.3M |
| Income taxes | — | — | — | — | — | — | $37,276 | — | — | −$37,276 | −$2 | −$147,539 |
| Net income | −$3.0M | −$2.4M | −$3.1M | −$2.7M | −$2.5M | −$3.3M | −$3.2M | −$3.5M | −$5.0M | −$4.6M | −$3.2M | −$2.3M |
| EBITDA | −$3.1M | −$2.4M | −$3.0M | −$2.7M | −$2.5M | −$3.3M | −$3.2M | −$3.5M | −$5.0M | −$4.6M | −$3.2M | −$2.3M |
| EPS (diluted) | −$1.11 | −$0.96 | −$1.21 | −$1.50 | −$0.13 | −$5.50 | −$1.17 | −$6.25 | −$9.00 | −$8.50 | −$0.23 | −$4.25 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 97.9% | — |
| Operating margin | — | — | — | — | — | — | −13,345.8% | — | — | — | −1,188.0% | — |
| Net margin | — | — | — | — | — | — | −13,254.2% | — | — | — | −1,123.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in INTS's financial statements (latest annual report filed March 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
INTS financial results
Intensity Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $11.6 million. Diluted earnings per share came to −$8.34.
See the INTS stock overview for the latest quote and news, or the INTS chart for price history and technical indicators.
INTS income statement FAQ
Does Intensity Therapeutics have revenue?
Intensity Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Intensity Therapeutics profitable?
No. Intensity Therapeutics reported a net loss of $11.6 million in fiscal 2025.
How much does Intensity Therapeutics spend on research and development?
Intensity Therapeutics spent $6.8 million on research and development in fiscal 2025.
What are Intensity Therapeutics's earnings per share?
Intensity Therapeutics earned $-8.34 per diluted share in fiscal 2025, compared with $-24.92 a year earlier.
When will Intensity Therapeutics report its next earnings?
Intensity Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does Intensity Therapeutics's fiscal year end?
Intensity Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 27, 2026.